RCM
SRPT icon

Reynolds Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Reynolds Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,100
Closed -$228K – 162
2015
Q3 		$228K Buy
+7,100
New +$241K 0.29% 120
2013
Q4 		– Sell
-4,500
Closed -$213K – 476
2013
Q3 		$213K Buy
+4,500
New +$173K 0.14% 325

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Reynolds Capital Management's SRPT Position: Q4 2015 in Review

Reynolds Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2015, closing a stake of 7,100 shares — an estimated $228K sold.

Reynolds Capital Management first reported a position in SRPT in Q3 2013 and held it in 2 quarters. The position peaked at $228K in Q3 2015. 151 funds tracked by Wall St. Rank hold SRPT as of Q4 2015.

  • Reynolds Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Reynolds Capital Management sold 7,100 Sarepta Therapeutics shares in Q4 2015, an estimated $228K.
  • Reynolds Capital Management first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 2 quarters.
  • Reynolds Capital Management's Sarepta Therapeutics position peaked at $228K in Q3 2015.
  • 151 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2015.

Based on Reynolds Capital Management's 13F filing for Q4 2015, filed 11 Jan 2016.